Literature DB >> 21490101

Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.

Yusuke Funaoka1, Naoya Sakamoto, Goki Suda, Yasuhiro Itsui, Mina Nakagawa, Sei Kakinuma, Takako Watanabe, Kako Mishima, Mayumi Ueyama, Izumi Onozuka, Sayuri Nitta, Akiko Kitazume, Kei Kiyohashi, Miyako Murakawa, Seishin Azuma, Kiichiro Tsuchiya, Mamoru Watanabe.   

Abstract

Substitution of amino acids 70 and 91 in the hepatitis C virus (HCV) core region is a significant predictor of poor responses to peginterferon-plus-ribavirin therapy, while their molecular mechanisms remain unclear. Here we investigated these differences in the response to alpha interferon (IFN) by using HCV cell culture with R70Q, R70H, and L91M substitutions. IFN treatment of cells transfected or infected with the wild type or the mutant HCV clones showed that the R70Q, R70H, and L91M core mutants were significantly more resistant than the wild type. Among HCV-transfected cells, intracellular HCV RNA levels were significantly higher for the core mutants than for the wild type, while HCV RNA in culture supernatant was significantly lower for these mutants than for the wild type. IFN-induced phosphorylation of STAT1 and STAT2 and expression of the interferon-inducible genes were significantly lower for the core mutants than for the wild type, suggesting cellular unresponsiveness to IFN. The expression level of an interferon signal attenuator, SOCS3, was significantly higher for the R70Q, R70H, and L91M mutants than for the wild type. Interleukin 6 (IL-6), which upregulates SOCS3, was significantly higher for the R70Q, R70H, and L91M mutants than for the wild type, suggesting interferon resistance, possibly through IL-6-induced, SOCS3-mediated suppression of interferon signaling. Expression levels of endoplasmic reticulum (ER) stress proteins were significantly higher in cells transfected with a core mutant than in those transfected with the wild type. In conclusion, HCV R70 and L91 core mutants were resistant to interferon in vitro, and the resistance may be induced by IL-6-induced upregulation of SOCS3. Those mechanisms may explain clinical interferon resistance of HCV core mutants.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21490101      PMCID: PMC3126319          DOI: 10.1128/JVI.02583-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

Review 1.  Alternate interferon signaling pathways.

Authors:  Dhananjaya V Kalvakolanu
Journal:  Pharmacol Ther       Date:  2003-10       Impact factor: 12.310

2.  Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication.

Authors:  Y Itsui; N Sakamoto; M Kurosaki; N Kanazawa; Y Tanabe; T Koyama; Y Takeda; M Nakagawa; S Kakinuma; Y Sekine; S Maekawa; N Enomoto; M Watanabe
Journal:  J Viral Hepat       Date:  2006-10       Impact factor: 3.728

Review 3.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones.

Authors:  Goki Suda; Naoya Sakamoto; Yasuhiro Itsui; Mina Nakagawa; Megumi Tasaka-Fujita; Yusuke Funaoka; Takako Watanabe; Sayuri Nitta; Kei Kiyohashi; Seishin Azuma; Sei Kakinuma; Kiichiro Tsuchiya; Michio Imamura; Nobuhiko Hiraga; Kazuaki Chayama; Mamoru Watanabe
Journal:  Virology       Date:  2010-08-25       Impact factor: 3.616

5.  Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.

Authors:  Sarah L George; Bruce R Bacon; Elizabeth M Brunt; Kusal L Mihindukulasuriya; Joyce Hoffmann; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

6.  Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.

Authors:  Yuki Nishimura-Sakurai; Naoya Sakamoto; Kaoru Mogushi; Satoshi Nagaie; Mina Nakagawa; Yasuhiro Itsui; Megumi Tasaka-Fujita; Yuko Onuki-Karakama; Goki Suda; Kako Mishima; Machi Yamamoto; Mayumi Ueyama; Yusuke Funaoka; Takako Watanabe; Seishin Azuma; Yuko Sekine-Osajima; Sei Kakinuma; Kiichiro Tsuchiya; Nobuyuki Enomoto; Hiroshi Tanaka; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2009-12-12       Impact factor: 7.527

7.  HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages.

Authors:  Li Chen; Sirikalaya Jarujaron; Xudong Wu; Lixin Sun; Weibin Zha; Guang Liang; Xuan Wang; Emily C Gurley; Elaine J Studer; Phillip B Hylemon; William M Pandak; Luyong Zhang; Guangji Wang; Xiaokun Li; Paul Dent; Huiping Zhou
Journal:  Biochem Pharmacol       Date:  2009-03-31       Impact factor: 5.858

8.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

9.  Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.

Authors:  Takashi Honda; Yoshiaki Katano; Fumihiro Urano; Mutsumi Murayama; Kazuhiko Hayashi; Masatoshi Ishigami; Isao Nakano; Kentaro Yoshioka; Hidenori Toyoda; Takashi Kumada; Hidemi Goto
Journal:  J Gastroenterol Hepatol       Date:  2007-07       Impact factor: 4.029

10.  Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles.

Authors:  Takahiro Masaki; Ryosuke Suzuki; Kyoko Murakami; Hideki Aizaki; Koji Ishii; Asako Murayama; Tomoko Date; Yoshiharu Matsuura; Tatsuo Miyamura; Takaji Wakita; Tetsuro Suzuki
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

View more
  23 in total

1.  Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection.

Authors:  Takako Watanabe; Naoya Sakamoto; Mina Nakagawa; Sei Kakinuma; Yasuhiro Itsui; Yuki Nishimura-Sakurai; Mayumi Ueyama; Yusuke Funaoka; Akiko Kitazume; Sayuri Nitta; Kei Kiyohashi; Miyako Murakawa; Seishin Azuma; Kiichiro Tsuchiya; Shinya Oooka; Mamoru Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

Review 2.  Impact of host and virus genome variability on HCV replication and response to interferon.

Authors:  Cameron J Schweitzer; T Jake Liang
Journal:  Curr Opin Virol       Date:  2013-07-06       Impact factor: 7.090

Review 3.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

4.  Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice.

Authors:  Hervé Lerat; Mohamed Rabah Imache; Jacqueline Polyte; Aurore Gaudin; Marion Mercey; Flora Donati; Camille Baudesson; Martin R Higgs; Alexandre Picard; Christophe Magnan; Fabienne Foufelle; Jean-Michel Pawlotsky
Journal:  J Biol Chem       Date:  2017-05-30       Impact factor: 5.157

5.  Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.

Authors:  Stéphanie B N Serre; Henrik B Krarup; Jens Bukh; Judith M Gottwein
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

Review 6.  Production and pathogenicity of hepatitis C virus core gene products.

Authors:  Hui-Chun Li; Hsin-Chieh Ma; Chee-Hing Yang; Shih-Yen Lo
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

7.  Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.

Authors:  Celia Perales; Nathan M Beach; Isabel Gallego; Maria Eugenia Soria; Josep Quer; Juan Ignacio Esteban; Charles Rice; Esteban Domingo; Julie Sheldon
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

Review 8.  Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

Authors:  Ahmed El-Shamy; Hak Hotta
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

9.  Silencing of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 promoter methylation.

Authors:  Takeshi Yoshikawa; Akemi Takata; Motoyuki Otsuka; Takahiro Kishikawa; Kentaro Kojima; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Sci Rep       Date:  2012-09-06       Impact factor: 4.379

Review 10.  Recent advances in understanding viral evasion of type I interferon.

Authors:  Kathryne E Taylor; Karen L Mossman
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.